Home Abortion Tags

Abortion

"KFF graphic with white text on a purple background that reads "Interactive Dashboard: Abortion in the United States." The graphic also has photo illustrations of the Supreme Court and abortion medication."

The Abortion in the United States Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade. It features a continuously-updated map tracking the status of abortion bans across the United States, as well as briefs on topics such as medication abortion, insurance coverage, ballot measures, legal developments, and racial and ethnic disparities. It also offers a jumping off point to the latest national and state-specific abortion policies and statistics. Visit the Dashboard →

View the Latest: Abortion

Filter

List Grid

111 - 120 of 292 Results

  • At the Supreme Court: What’s at Stake for Emergency Abortion Care?

    News Release

    On April 24, the Supreme Court will hear Idaho v. United States—the second case this term involving access to abortion. In a new brief, KFF examines what’s at stake, focusing on whether the Emergency Medical Treatment and Active Labor Act (EMTALA)—a federal law requiring nearly all hospitals to ensure emergency room patients are stable before they are discharged from hospital care—preempts state abortion laws.  The new brief reviews the background on the case and EMTALA,…

  • Abortion Back at SCOTUS: Can States Ban Emergency Abortion Care for Pregnant Patients?

    Issue Brief

    On April 24, 2024, the Supreme Court will hear the second case this term involving access to abortion: Idaho v. United States. At stake in this case is whether the Emergency Medical Treatment and Active Labor Act, a federal law requiring hospitals to provide stabilizing treatment to patients who present to their emergency rooms, preempts state abortion laws and requires hospitals that accept Medicare to provide abortion care when it is necessary to stabilize a…

  • Could the Comstock Act Be Used to Limit Abortion Access Nationwide?

    News Release

    In a new brief, KFF examines how the Comstock Act, an 1873 anti-vice law banning the mailing of obscene matter and articles, could be used by an anti-abortion presidential administration to sharply restrict the availability of abortion nationwide.  The Biden Administration’s Department of Justice has said the Comstock Act should not be interpreted literally with respect to abortion and has not enforced it. However, a future administration opposed to abortion rights could interpret the law…

  • The Comstock Act: Implications for Abortion Care Nationwide 

    Issue Brief

    This brief provides background on the Comstock Act, reviews how it has been interpreted by the Biden Administration’s DOJ, and considers how it could be enforced by an administration that is hostile toward abortion to severely restrict the distribution of drugs and supplies used for abortion, with implications for abortion access in all states across the country.

  • One in Five Women of Reproductive Age in States with Abortion Bans Say They or Someone They Know Has Had Difficulty Accessing an Abortion Since Dobbs

    News Release

    According to new KFF polling, in states with abortion bans, one in five (21%) women of reproductive age (18 to 49) and one in seven (14%) of all women say either they or someone they know has had difficulty accessing an abortion since the Supreme Court overturned Roe v. Wade. The survey finds that among all women, including in states where abortion remains broadly legal or limited by gestational period, 8% say they or someone…

  • The Supreme Court, Medication Abortion, and the FDA: What’s at Stake?

    News Release

    In advance of oral arguments about access to medication abortion before the Supreme Court on March 26, KFF examines how a Court ruling for the plaintiffs would limit access to mifepristone blocking its use in telehealth and distribution through pharmacies, including in states where abortion is legal and protected. In addition, it could potentially weaken the role of the Food and Drug Administration (FDA) in drug reviews—something the Court has never done before. As part…